Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence.
Wern Yew DingJose Miguel Rivera-CaravacaFrancisco MarínGuowei LiVanessa RoldánGregory Y H LipPublished in: British journal of clinical pharmacology (2021)
Overall, the NNTnet approach in AF incorporates information regarding baseline risk of stroke and major bleeding, and relative effects of OAC with the potential to include multiple additional outcomes and weighting of events based on their perceived effects by individual patients.
Keyphrases
- atrial fibrillation
- clinical trial
- oral anticoagulants
- catheter ablation
- left atrial
- end stage renal disease
- left atrial appendage
- direct oral anticoagulants
- ejection fraction
- heart failure
- chronic kidney disease
- percutaneous coronary intervention
- newly diagnosed
- depressive symptoms
- peritoneal dialysis
- prognostic factors
- social support
- mental health
- health information
- patient reported outcomes
- venous thromboembolism
- type diabetes
- risk assessment
- coronary artery disease
- mitral valve
- double blind
- cerebral ischemia
- phase ii